NO20064192L - Agonister og antagonister av P28, EB13 og WSX/TCCR til behandling av immunforstyrrelser - Google Patents

Agonister og antagonister av P28, EB13 og WSX/TCCR til behandling av immunforstyrrelser

Info

Publication number
NO20064192L
NO20064192L NO20064192A NO20064192A NO20064192L NO 20064192 L NO20064192 L NO 20064192L NO 20064192 A NO20064192 A NO 20064192A NO 20064192 A NO20064192 A NO 20064192A NO 20064192 L NO20064192 L NO 20064192L
Authority
NO
Norway
Prior art keywords
antagonists
agonists
tccr
wsx
treatment
Prior art date
Application number
NO20064192A
Other languages
English (en)
Norwegian (no)
Inventor
Robert A Kastelein
Terrill K Mccianahan
Stefan Pflanz
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34886193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064192(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20064192L publication Critical patent/NO20064192L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20064192A 2004-02-17 2006-09-15 Agonister og antagonister av P28, EB13 og WSX/TCCR til behandling av immunforstyrrelser NO20064192L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54576204P 2004-02-17 2004-02-17
PCT/US2005/004902 WO2005079848A2 (en) 2004-02-17 2005-02-15 Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders

Publications (1)

Publication Number Publication Date
NO20064192L true NO20064192L (no) 2006-11-16

Family

ID=34886193

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064192A NO20064192L (no) 2004-02-17 2006-09-15 Agonister og antagonister av P28, EB13 og WSX/TCCR til behandling av immunforstyrrelser

Country Status (11)

Country Link
US (1) US20050214296A1 (pt)
EP (1) EP1755641A2 (pt)
JP (1) JP2007523169A (pt)
CN (1) CN1921886A (pt)
AU (1) AU2005215771A1 (pt)
BR (1) BRPI0507776A (pt)
CA (1) CA2555421A1 (pt)
NO (1) NO20064192L (pt)
TW (1) TW200531679A (pt)
WO (1) WO2005079848A2 (pt)
ZA (1) ZA200606833B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069173A2 (en) 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
JP2009543579A (ja) * 2006-07-19 2009-12-10 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
WO2008025033A2 (en) * 2006-08-25 2008-02-28 Zymogenetics, Inc. Use of il-27 antagonists for the manufacture of a medicament for the treatment of aplastic anemia
AU2007298571B2 (en) 2006-09-22 2012-06-07 St. Jude Children's Research Hospital Modulating regulatory T cell activity via Interleukin 35
WO2009052487A2 (en) * 2007-10-18 2009-04-23 University Of South Florida Method of detecting oncogenesis of hematopoietic cells
WO2010065116A2 (en) * 2008-12-02 2010-06-10 The Trustees Of The University Of Pennsylvania The use of il-27-p28 to antagonize il-6 mediated signaling
WO2010118243A2 (en) * 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
EP2480888B1 (en) 2009-09-25 2016-11-30 XOMA Technology Ltd. Screening methods
JP5669055B2 (ja) * 2009-10-27 2015-02-12 国立大学法人佐賀大学 ダブルノックアウト非ヒト動物
JP5822248B2 (ja) * 2009-10-27 2015-11-24 国立大学法人佐賀大学 ノックアウト非ヒト動物
US20130183326A9 (en) 2009-11-20 2013-07-18 St. Jude Children's Research Hospital Methods and compositions for modulating the activity of the interleukin-35 receptor complex
WO2011133931A1 (en) * 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
CN102337268B (zh) * 2010-07-16 2013-04-24 北京大学 人类ctrp4基因、其编码的蛋白质及它们的应用
AU2012205384B2 (en) * 2011-01-14 2015-09-10 Five Prime Therapeutics, Inc. IL-27 antagonists for treating inflammatory diseases
JP6083784B2 (ja) * 2012-07-02 2017-02-22 国立研究開発法人理化学研究所 慢性閉塞性肺疾患の増悪指標の検出方法
CN102816794A (zh) * 2012-08-23 2012-12-12 南开大学 一种鼠源il-27重组蛋白真核表达载体及构建方法
WO2014070874A1 (en) * 2012-10-31 2014-05-08 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways
JP6187985B2 (ja) * 2015-07-14 2017-08-30 国立大学法人佐賀大学 ノックアウト非ヒト動物
CN112512571B (zh) * 2018-03-22 2025-02-07 表面肿瘤学有限责任公司 抗il-27抗体及其用途
EP3894440A4 (en) * 2018-12-13 2022-09-07 Surface Oncology, Inc. ANTI-IL-27 ANTIBODIES AND USES THEREOF
CN110305864A (zh) * 2019-07-05 2019-10-08 山东省寄生虫病防治研究所 一种用于干扰DNALI1基因表达的siRNA及其在抑制细胞增殖和迁移中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744301A (en) * 1992-11-25 1998-04-28 Brigham And Women's Hospital Methods of detection of epstein barr virus induced genes expressed in the placenta
WO1997013859A1 (en) * 1995-10-11 1997-04-17 Brigham And Women's Hospital, Inc. A novel haematopoietic cytokine and uses therefor
AU721129B2 (en) * 1996-01-08 2000-06-22 Genentech Inc. WSX receptor and ligands
US5874252A (en) * 1997-07-29 1999-02-23 Smithkline Beecham Corporation Splicing variant of the Epstein-Barr virus-induced G-protein coupled receptor
US20030008343A1 (en) * 1999-07-30 2003-01-09 Timans Jacqueline C Mammalian cytokines; related reagents
MXPA02001146A (es) * 1999-07-30 2002-08-20 Schering Corp Citosinas de mamifero, reactivos relacionados.
US7148330B2 (en) * 1999-07-30 2006-12-12 Schering Corporation Binding compounds for IL-27
KR100874280B1 (ko) * 1999-10-20 2008-12-18 제넨테크, 인크. Ｔ 헬퍼 세포 매개 질환의 치료를 위한 ｔ 세포 분화의조절
US7086337B2 (en) * 2000-09-28 2006-08-08 Klein John M Non-lethal projectile ammunition
AU2003301114B2 (en) * 2002-12-31 2010-03-18 Merck Sharp & Dohme Corp. Uses of mammalian cytokine; related reagents

Also Published As

Publication number Publication date
US20050214296A1 (en) 2005-09-29
ZA200606833B (en) 2008-05-28
BRPI0507776A (pt) 2007-07-10
JP2007523169A (ja) 2007-08-16
CA2555421A1 (en) 2005-09-01
EP1755641A2 (en) 2007-02-28
WO2005079848A3 (en) 2005-12-15
AU2005215771A1 (en) 2005-09-01
WO2005079848A9 (en) 2006-12-07
CN1921886A (zh) 2007-02-28
WO2005079848A2 (en) 2005-09-01
TW200531679A (en) 2005-10-01

Similar Documents

Publication Publication Date Title
NO20064192L (no) Agonister og antagonister av P28, EB13 og WSX/TCCR til behandling av immunforstyrrelser
NO20070950L (no) Preparater og fremgangsmater for anvendelse av angiopoietinlignende-4-protein.
ATE496636T1 (de) Verwendung von agonisten und antagonisten von interleukin-33 (il-33)
MX2021015992A (es) Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico.
MXPA05010035A (es) Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21.
IL258702B (en) A pump system for use with organ care systems
CR8891A (es) Antagonismo de la actividad del receptor de interleuquina 21
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
ATE322258T1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
PH12022550359A1 (en) Nonpeptide somatostatin type 5 receptor agonists and uses thereof
TR200909479T2 (tr) Sinerjistik kombinasyon.
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
NO20084374L (no) Imidazoltiazolforbindelser for behandling av sykdom
BRPI0511477A (pt) compostos e composições como moduladores de ppar
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
IL181629A0 (en) Compositions and methods for the diagnosis and tretment of tumor
NO20070330L (no) Retinalderivater og fremgangsmater for anvendelse derav til behandling av synsforstyrrelser
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
EP1589998A4 (en) USE OF ANIMAL CYTOKINE; RELATED REAGENTS
NO20054371L (no) Somatostatin-dopamin kimaere analoger
ATE375786T1 (de) Chitin-mikropartikel und ihre medizinische verwendung
BR0314783A (pt) Pirróis 3,4-dissubstituìdos e seu uso no tratamento de doenças inflamatórias
EA200601894A1 (ru) Производные пиперазинилпиперидина в качестве антагонистов хемокинового рецептора
MX2024006212A (es) Métodos para usar agonistas del rar? para tratamiento del cáncer.
CY1109803T1 (el) Φαρμακευτικες συνθεσεις που βασιζονται σε ανταγωνιστες νκ2 για παιδιατρικη χρηση

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application